Lineage Cell Therapeutics
LCTX
LCTX
110 hedge funds and large institutions have $112M invested in Lineage Cell Therapeutics in 2022 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 20 increasing their positions, 39 reducing their positions, and 25 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less funds holding in top 10
Funds holding in top 10: →
38% less capital invested
Capital invested by funds: $182M → $112M (-$69.4M)
49% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 39
52% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 25
Holders
110
Holding in Top 10
2
Calls
$389K
Puts
$117K
Top Buyers
| 1 | +$1.43M | |
| 2 | +$1.17M | |
| 3 | +$872K | |
| 4 |
Nuveen Asset Management
Chicago,
Illinois
|
+$197K |
| 5 |
AC
Aristides Capital
Louisville,
Kentucky
|
+$154K |
Top Sellers
| 1 | -$1.32M | |
| 2 | -$747K | |
| 3 | -$731K | |
| 4 |
Allspring Global Investments
Charlotte,
North Carolina
|
-$542K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$495K |